Penile Carcinoma Clinical Trials

6 recruitingLast updated: June 17, 2026

There are 6 actively recruiting penile carcinoma clinical trials across 5 countries. Studies span Phase 2, Phase 1. Top locations include Los Angeles, California, United States, Alcoa, Tennessee, United States, Allentown, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Penile Carcinoma Trials at a Glance

6 actively recruiting trials for penile carcinoma are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Los Angeles, Alcoa, and Allentown. Lead sponsors running penile carcinoma studies include German Cancer Research Center, H. Lee Moffitt Cancer Center and Research Institute, and Jonsson Comprehensive Cancer Center.

Browse penile carcinoma trials by phase

Treatments under study

About Penile Carcinoma Clinical Trials

Looking for clinical trials for Penile Carcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Penile Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Penile Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 2

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Penile CancerUrogenital NeoplasmsPenile Squamous Cell Carcinoma+3 more
The Netherlands Cancer Institute27 enrolled2 locationsNCT06353906
Recruiting
Phase 2

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Penile Carcinoma
H. Lee Moffitt Cancer Center and Research Institute25 enrolled2 locationsNCT05526989
Recruiting
Phase 1

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+31 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT07118176
Recruiting
Phase 1

FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer

Breast CarcinomaColorectal, CancerPenile Carcinoma+1 more
German Cancer Research Center89 enrolled1 locationNCT05999396